Loading patent…
AssigneeRegeneron Pharmaceuticals, Inc.
InventorsKevin Bray, Frank Delfino, David DiLillo, Thomas Craig Meagher
Estimating the term…
MAGE-A4, or Melanoma-Associated Antigen A4, is a cancer-testis antigen (CTA) on the X chromosome. The present disclosure provides MAGE-A4-specific chimeric antigen receptors and cells expressing such chimeric antigen receptors. In certain embodiments, engineered cells expressing the chimeric antigen receptors of the present disclosure are capable of inhibiting the growth of tumors expressing MAGE-A4. The engineered cells of the present disclosure are useful for the treatment of diseases and disorders in which an upregulated or induced MAGE-A4-targeted immune response is desired and/or therapeutically beneficial. For example, engineered cells expressing the MAGE-A4-specific chimeric antigen receptors of the present disclosure are useful for the treatment of various cancers.
A Melanoma-Associated Antigen A4 (MAGE-A4)-specific chimeric antigen receptor comprising, from N-terminus to C-terminus:
An antibody or antigen-binding fragment thereof that specifically binds Melanoma-Associated Antigen A4 (MAGE-A4), wherein the antibody or antigen-binding fragment comprises a heavy chain variable region (HCVR) comprising three heavy chain complementarity determining regions, HCDR1, HCDR2 and HCDR3, comprising the amino acid sequences of SEQ ID NOs:
An antibody or antigen-binding fragment thereof that specifically binds Melanoma-Associated Antigen A4 (MAGE-A4), wherein the antibody or antigen-binding fragment comprises a heavy chain variable region (HCVR) comprising three heavy chain complementarity determining regions, HCDR1, HCDR2 and HCDR3, comprising the amino acid sequences of SEQ ID NOs:
Dependencies are inferred from the claim text.